Lilly's New Pill Foundayo: A Game Changer in Weight Loss?

Eli Lilly's latest study reveals that patients switching from injectable GLP-1 medications to the company's new oral weight-loss pill, Foundayo, maintain significant weight reduction. The innovative pill rivals Novo Nordisk's Wegovy and demonstrates effectiveness in prolonging weight management, with projections reaching $100 billion in sales annually within a decade.

On Tuesday, Eli Lilly released results from a late-stage trial showing that their new weight-loss pill, Foundayo, effectively maintains weight loss for patients transitioning from injectable GLP-1 medications. Notably, individuals switching from Novo Nordisk's Wegovy regained an average of only two pounds after a year, highlighting the pill's potential.

The Indianapolis-based pharmaceutical company introduced Foundayo, chemically known as orforglipron, into the U.S. market in April. Positioned as a direct competitor to Danish drugmaker Novo's Wegovy, the oral pills cater to patients reluctant to use injections. Industry analysts predict the weight-loss market could soar past $100 billion annually within the next decade.

Data presented at the European Congress on Obesity in Istanbul indicated substantial weight retention rates for patients switching to Foundayo. Eli Lilly's President of Cardiometabolic Health, Kenneth Custer, emphasized the pill gives patients more flexibility in managing their weight loss treatment plans.